Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem
Chai Discovery is treating drug design as a scaling problem, prioritizing model simplicity over complexity
“one of the exciting things we're trying to do at Chai is to make the drug discovery process like a little bit more like engineering”
Chai Discovery co-founders argue that drug design is another domain where AI scaling laws apply, and that their predecessor model Chai 1's 23-submodule architecture was too complex to scale effectively. Their core thesis is that biology needs the same abstraction layers that made software engineering fast, replacing serendipitous trial-and-error with systematic, engineered iteration. This mirrors the 'bitter lesson' pattern seen across AI domains: simplicity and scale beat hand-crafted complexity.